Matt Abernethy
Chief Financial Officer; Director · 5 filings · Latest: Sep 11, 2026
FATE THERAPEUTICS INC
NEUROCRINE BIOSCIENCES INC
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
NBIX | Matt Abernethy | Chief Financial Officer | Sep 14, 2026 | Sale | $157.20 | 2,311 | $363.3K | 42,808 | |
NBIX | MATTHEW C ABERNETHY | — | Sep 14, 2026 | Proposed Sale | $156.22 | 2,311 | $361.0K | — | |
NBIX | Matt Abernethy | Chief Financial Officer | Feb 13, 2026 | Option Exercise | $0.00 | 4,807 | — | 41,676 | |
NBIX | Matt Abernethy | Chief Financial Officer | Feb 12, 2026 | Option Exercise | $0.00 | 2,133 | — | 39,230 | |
NBIX | Matt Abernethy | Chief Financial Officer | Jan 31, 2026 | Option Exercise | $0.00 | 2,437 | — | 38,465 | |
NBIX | MATTHEW ABERNETHY | — | Feb 13, 2025 | Proposed Sale | $117.18 | 1,352 | $158.4K | — | |
NBIX | MATTHEW C ABERNETHY | — | Feb 13, 2025 | Proposed Sale | $117.18 | 1,206 | $141.3K | — | |
NBIX | MATTHEW C ABERNETHY | — | Feb 10, 2025 | Proposed Sale | $122.62 | 980 | $120.2K | — | |
NBIX | MATTHEW C ABERNETHY | — | Jan 31, 2025 | Proposed Sale | $153.29 | 1,283 | $196.7K | — |